心血管危险业尿素和预防.ppt

心血管疾病危险因素和预防;;前言;前言;前言;前言;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;预防;预防;心血管病总体危险;重要心血管病危险因素;血压水平的定义与分类;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;;诊 断;心血管病的危险因素 ;心血管病的危险因素;靶器官损害 ;并存的临床情况 ;并存的临床情况;并存的临床情况;危险分层;;治疗的意义 ;改善生活行为;;降压药治疗对象;血压控制目标值;降压药物治疗;常用利尿剂;常用β受体阻滞剂;常用钙通道阻滞剂;常用ACEI;AT1拮抗剂;降压治疗方案;吸烟及其防治原则;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;血脂异常;血脂异常;血脂异常的临床分型;血脂水平分层标准(TC);血脂水平分层标准(LDL-C);血脂水平分层标准(HDL-C);血脂水平分层标准(TG);血脂异常危险分层方案;血脂异常危险因素;冠心病等危症;血脂异常患者开始调脂治疗的TC和LDL-C值及其目标值;治疗性生活方式改变(therapeutic life-style change，TLC);膳食评价;改变膳食的TLC措施可获得降低LDL-C的效果;调脂药物的分类 HMG-CoA还原酶抑制剂(他汀类) 贝丁酸类(贝特类) 烟酸类 胆酸螯合剂（树脂类) 胆固醇吸收抑制剂 其他 ;他汀类药物对高胆固醇血症患者脂质和脂蛋白影响的比较;他汀类药物降低LDL-C水平30％～40％所需剂量(标准剂量);常用的贝特类药物;常用的烟酸类药物;常用的胆酸螯合剂药物;胆固醇吸收抑制剂;其他调脂药（普罗布考）;其他调脂药（n-3脂肪酸）;调脂药物的联合应用;血脂异常治疗的其他措施;;糖尿病及其防治原则;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;糖尿病诊断;糖尿病的治疗;糖尿病的药物治疗原则;糖尿病的药物治疗原则;糖尿病的药物治疗原则;不平衡膳食及其防治原则;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;超重和肥胖及其防治原则;;缺乏体力活动;体力活动建议;体力活动建议;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;注意事项;肾脏损害;Evaluation only. Created with Aspose.Slides for .NET 3.5 Client Profile 5.2.0.0. Copyright 2004-2011 Aspose Pty Ltd.;CKD的防治原则;代谢综合征;代谢综合征的治疗;炎症因子;hs-CRP;凝血因子;血栓形成;抗栓抗凝治疗;抗栓药物;与遗传有关的因素;遗传信息在心血管病防治中的应用;社会心理因素;心理应激增加心血管病危险的机制;预防和缓解心理压力的主要方法;谢谢